nDatalyze Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

nDatalyze has a total shareholder equity of CA$687.9K and total debt of CA$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CA$751.5K and CA$63.6K respectively.

Anahtar bilgiler

Borç/özkaynak oranı

CA$0

Borç

Faiz karşılama oranı	n/a
Nakit	CA$644.51k
Eşitlik	CA$687.92k
Toplam yükümlülükler	CA$63.61k
Toplam varlıklar	CA$751.53k

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Is MedXtractor Corp.'s (CSE:MXT) 1.1% ROE Worse Than Average?

Jan 14

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: NDAT's short term assets (CA$672.6K) exceed its short term liabilities (CA$63.6K).

Uzun Vadeli Yükümlülükler: NDAT has no long term liabilities.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: NDAT is debt free.

Borcun Azaltılması: NDAT has not had any debt for past 5 years.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: NDAT has sufficient cash runway for more than a year based on its current free cash flow.

Tahmini Nakit Akışı: NDAT has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 28.8% each year.

nDatalyze Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Second quarter 2025 earnings released: CA$0.005 loss per share (vs CA$0.004 profit in 2Q 2024)

nDatalyze Corp. Announces Positive Clinical Study Results, and Mindbalanced Update

New minor risk - Share price stability

nDatalyze Corp. Announces Change in President

Full year 2024 earnings released: CA$0.004 loss per share (vs CA$0.032 loss in FY 2023)

nDatalyze Corp. Announces Clinical Study Update

nDatalyze Corp. Updates the Clinical Study

nDatalyze Corp. announced that it has received CAD 0.20625 million in funding

nDatalyze Corp. announced that it expects to receive CAD 0.20625 million in funding

Ndatalyze Corp. Announces Executive Changes

nDatalyze Corp. (CNSX:NDAT) completed the acquisition of Mindbalanced Inc.

New minor risk - Share price stability

nDatalyze Corp., Annual General Meeting, Mar 14, 2024

Third quarter 2024 earnings released: CA$0.004 loss per share (vs CA$0.006 loss in 3Q 2023)

Insufficient new directors

New minor risk - Shareholder dilution

nDatalyze Corp. announced that it has received CAD 0.2778 million in funding

nDatalyze Corp. Announces Appointment of Dr. Keith Courtney as President and Chief Psychiatric Officer

Second quarter 2024 earnings released: EPS: CA$0.004 (vs CA$0.006 loss in 2Q 2023)

nDatalyze Corp. Advances Its Clinical Study Process

nDatalyze Corp. Begins a Clinical Study Process

nDatalyze Corp. Begins a Clinical Study Process

Full year 2023 earnings released: CA$0.032 loss per share (vs CA$0.032 loss in FY 2022)

Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.001 loss in 3Q 2022)

nDatalyze Corp. Anticipates YMI ChatGPT Testing

nDatalyze Corp. Announces Two Video Initiatives to Augment Its Phase 2 Marketing Program

nDatalyze Corp. Announces Canada-Wide Release of YMI

Second quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.003 loss in 2Q 2022)

nDatalyze Corp., Annual General Meeting, Nov 30, 2022

First quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.002 loss in 1Q 2022)

Full year 2022 earnings released: CA$0.032 loss per share (vs CA$0.027 loss in FY 2021)

nDatalyze Announces YMI mHealth Application Beta is Now Online

nDatalyze Corp. announced that it expects to receive CAD 1.25 million in funding

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

nDatalyze Announces Successful Proof-Of-Concept and Progress Update

Second quarter 2022 earnings released: CA$0.003 loss per share (vs CA$0.001 profit in 2Q 2021)

First quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.001 profit in 1Q 2021)

Medxtractor Corp Updates Reference Record Collection Progress

Full year 2021 earnings released: CA$0.027 loss per share (vs CA$0.002 loss in FY 2020)

MedXtractor Corp. announced that it has received CAD 1.815 million in funding

President exercised options and sold CA$78k worth of stock

Chief Financial Officer recently sold CA$99k worth of stock

New 90-day high: CA$0.27

MedXtractor Corp. announced that it expects to receive CAD 1.6 million in funding

Medxtractor Corp. Updates the SHAMAN Psychedelics Artificial Intelligence Project

New 90-day high: CA$0.24

New 90-day high: CA$0.21

Is MedXtractor Corp.'s (CSE:MXT) 1.1% ROE Worse Than Average?

Medxtractor Corp. Announces Commencement of "SHAMAN"

Third quarter 2021 earnings released: CA$0.001 loss per share

MedXtractor Corp. Announces Board Changes

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin